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Polyfluoroalkyl compounds (PFCs) are a 
group of organic chemicals that contain a flu-
orinated hydrophobic carbon chain attached 
to hydrophilic heads. Certain PFCs are persis-
tent and nonbiodegradable and can be trans-
ported over long distances in the environment 
(Egeghy and Lorber 2010). Because of these 
properties, some PFCs have been included 
in the Stockholm Convention on Persistent 
Organic Pollutants (POPs) (Stockholm 
Convention 2008). Like other POPs, some 
PFCs have a long serum half-life in humans 
ranging from 3.5 to 7.3 years (Olsen et al. 
2007). PFCs include perfluorooctane sulfonic 
acid (PFOS) and its precursor perfluorooctane 
sulfonamide (PFOSA), perfluorooctanoic acid 
(PFOA), perfluorononanoic acid (PFNA), 
and perfluorohexane sulfonic acid (PFHxS) 
(Fromme et al. 2009). The most frequently 
detected PFCs in humans are PFOS and 
PFOA (Fromme et al. 2009).
For the last 50 years, PFCs have been 
used worldwide in various settings (Kannan 
et al. 2004; Kato et al. 2009a; Lindstrom et al. 
2011; Schecter et al. 2010), primarily as surfac-
tants and emulsifiers. Some examples include 
their use in food packaging, nonstick coatings, 
firefighting foams, paper coatings, and textile 
coatings (especially carpet and upholstery) and 
in personal care products such as cosmetics, 
lotions, nail polish, and shaving cream (Ohio 
Department of Health 2006). Because of 
recent findings of the toxicity of these com-
pounds, efforts are being made to reduce or 
eliminate their use (Lindstrom et al. 2011). 
In 2002, for example, 3M, a major North 
American PFC producer, ended production of 
PFOS-related compounds, the ammonium salt 
of PFOA, and other perfluorooctanesulfonyl 
fluoride–based products (3M Company 2000; 
Prevedouros et al. 2005). Studies conducted 
after 2002 have shown PFOA and PFOS 
serum concentrations in adults to be lower 
than reported before 2002, whereas PFNA 
concentrations appear to be increasing (Calafat 
et al. 2007b; Haug et al. 2009; Kato et al. 
2011). Therefore, although steps are being 
taken that may decrease the presence of PFCs, 
these toxic compounds continue to persist in 
our environment (Lindstrom et al. 2011).
Human exposure to PFCs can occur 
through indoor and outdoor air inhalation, 
dust inhalation ingestion, and ingestion of 
contaminated food or water (Fromme et al. 
2009). Major exposure pathways for children 
may also include dust and soil ingestion, pla-
cental transfer, and breast-feeding (Fromme 
et al. 2009; Hanssen et al. 2010; Kärrman 
et al. 2007; Monroy et al. 2008; Zhang et al. 
2010a). PFCs have been detected in infant, 
child, and adult blood or serum samples and 
in adult liver and breast milk (Frisbee et al. 
2009; Kärrman et al. 2010; Liu et al. 2010; 
Llorca et al. 2010; Tao et al. 2008a, 2008b; 
Zhang et al. 2010b). Serum concentrations of 
some PFCs, such as PFOA, have been associ-
ated with age, sex, and race (Calafat et al. 
2007a, 2007b; Steenland et al. 2009).
Some studies have examined associations 
between PFC exposures in children and health 
effects, with inconsistent results (Lindstrom 
et al. 2011; Steenland et al. 2009). A recent 
study by Gump et al. (2011) reported an associ-
ation between PFC levels and impaired response 
inhibition in children. A cross-sectional study 
measuring sexual maturation in a 2005–2006 
survey of 3,076 Mid-Ohio Valley boys and 
2,931 Mid-Ohio Valley girls 8–18 years of age 
who were exposed to drinking water contami-
nated with PFOA reported that PFOA and 
PFOS serum concentrations were associated 
with later sexual maturation in boys and girls 
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Background: For > 50 years, polyfluoroalkyl compounds (PFCs) have been used worldwide, 
mainly as surfactants and emulsifiers, and human exposure to some PFCs is widespread.
oBjectives: Our goal was to report PFC serum concentrations from a convenience sample of 
Dallas, Texas, children from birth to < 13 years of age, and to examine age and sex differences in 
PFC concentrations.
Methods: We analyzed 300 serum samples collected in 2009 for eight PFCs by online solid phase 
extraction–high performance liquid chromatography–isotope dilution–tandem mass spectrometry.
results: Perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), per-
fluorooctanoic acid (PFOA), and perfluorononanoic acid (PFNA) were detected in > 92% of par-
ticipants; the other PFCs measured were detected less frequently. Overall median concentrations 
of PFOS (4.1 ng/mL) were higher than those for PFOA (2.85 ng/mL), PFNA (1.2 ng/mL), and 
PFHxS (1.2 ng/mL). For PFOS, PFOA, PFNA, and PFHxS, we found no significant differences 
(p < 0.05) by sex, significantly increasing concentrations for all four chemicals by age, and signifi-
cantly positive correlations between all four compounds.
conclusions: We found no significant differences in the serum concentrations of PFOS, PFOA, 
PFNA, and PFHxS by sex, but increasing concentrations with age. Our results suggest that these 
300 Texas children from birth through 12 years of age continued to be exposed to several PFCs in 
late 2009, years after changes in production of some PFCs in the United States.
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(Lopez-Espinosa et al. 2011). In contrast, a 
study of 218 girls reporting menarche before 
the age of 11.5 years, and 230 girls report-
ing menarche after the age of 11.5 years from 
the general U.K. population born between 
1 April 1991 and 31 December 1992 showed 
no association between prenatal PFC exposure 
and age at menarche (Christensen et al. 2011). 
An American study by Pinney et al. (2009) 
reported that serum PFOA concentrations 
were positively correlated with earlier breast 
maturation and inversely correlated with body 
mass index in 689 girls 6–7 years of age.
Assessing human exposure to PFCs can 
provide useful information for understanding 
their potential adverse health effects. However, 
such exposure data are rather limited for infants 
and young children. In the United States, the 
Centers for Disease Control and Prevention 
(CDC), as part of the National Health and 
Nutrition Examination Survey (NHANES), 
provides information on PFC exposures among 
older children based on serum concentrations 
in a representative sample of the U.S. general 
population ≥ 12 years of age (Kato et al. 2011). 
For younger children within the general U.S. 
population, data on the concentrations of PFCs 
are available from 598 children, 2–12 years 
of age, recruited from a multicenter clinical 
trial in 1994–1995 (Olsen et al. 2004) and 
from pooled sera collected from 936 children 
3–11 years of age who were NHANES partici-
pants in 2001–2002 (Kato et al. 2009a). More 
recently, as part of the C8 Health Study, serum 
concentrations of PFCs were measured in study 
area residents, including children 1–13 years of 
age (Frisbee et al. 2009, 2010). The C8 Health 
Project was created and funded by a settlement 
that resulted from PFOA-contaminated drink-
ing water and included > 60,000 participants. 
However, levels in this study population are 
not likely to be representative of U.S. children 
as a whole because of relatively high environ-
mental exposures.
For this study, we measured serum con-
centrations of eight PFCs in a convenience 
sample of 300 infants and children from 
birth through 12 years of age who had blood 
 samples collected at a children’s medical cen-
ter in Dallas, Texas, in 2009.
Methods
This study was reviewed and found to be 
exempt from informed consent requirements 
by the institutional review board committees 
for the protection of human subjects at the 
University of Texas Southwestern Medical 
Center, the University of Texas Health 
Science Center at Houston, and the CDC.
Sample collection. Serum samples 
were collected from August 2009 through 
November 2009 at Children’s Medical Center 
in Dallas, Texas, from a convenience sample 
of 300 children < 13 years of age undergo-
ing blood tests. It is unknown if serum was 
collected from healthy children or if these 
children were receiving evaluation or treat-
ment for illness. Samples were stored frozen 
at –80°C after collection, and approximately 
0.5–1.0 mL residual serum from each child 
was sent on dry ice to CDC for chemical 
analysis. No demographic or anthropomet-
ric information was available other than the 
child’s date of birth (DOB), date of serum 
collection, age (calculated based on DOB and 
date of serum collection), and sex.
Chemical analyses. Serum concentrations 
of eight PFCs—PFOSA, 2-(N-ethyl-perfluoro-
octane sulfonamido) acetic acid (Et-PFOSA-
AcOH), 2-(N-methyl-perfluorooctane 
sulfonamido) acetic acid (Me-PFOSA-
AcOH), PFHxS, PFOS, PFOA, PFNA, and 
perfluoro decanoic acid (PFDA)—were meas-
ured by online solid phase extraction–high 
performance liquid chromatography–isotope 
dilution–tandem mass spectrometry as previ-
ously described (Kato et al. 2011). The limits 
of detection (LOD) in 0.1 mL serum were 
0.1 ng/mL (PFOA, PFNA, PFHxS, PFOSA) 
and 0.2 ng/mL (PFOS, PFDA, Et-PFOSA-
AcOH, Me-PFOSA-AcOH).
Statistical analyses. Concentrations below 
the LOD were assigned a value equal to the 
LOD divided by the square root of 2 for sta-
tistical analyses. Statistical analyses were done 
only on chemicals with > 92% detection rates, 
except for a comparison of Me-PFOSA-AcOH 
concentrations in children ≤ 4 years of age 
versus > 4 years of age. We calculated uni-
variate statistics, including medians, ranges, 
and detection frequencies, for each PFC. 
Analyses were conducted separately for boys 
and girls and for boys and girls combined. 
Because PFC concentrations were highly 
skewed, we used the Wilcoxon rank-sum test 
to compare PFC concentrations between boys 
and girls. The Kruskal–Wallis test, a non-
parametric analysis of variance, was used to 
examine overall differences in median con-
centrations among age groups (0 to < 3 years, 
3 to < 6 years, 6 to < 9 years, and 9 to < 13 
years) for girls, boys, and girls and boys com-
bined. When the Kruskal–Wallis test was sig-
nificant, we used Dunn’s method to perform 
a nonparametric test of differences among 
multiple groups with unequal sample sizes 
and tied ranks (Elliott and Hynan 2011). 
To assess associations between age and indi-
vidual PFC serum concentrations, we cal-
culated Spearman rank-order correlations. 
IBM© SPSS Statistics version 19 (SPSS, Inc., 
IBM, Chicago, IL,) and SAS version 9.2 (SAS 
Institute Inc., Cary, NC) were used to analyze 
these data; significance was set to p < 0.05 
unless otherwise noted.
Results
We measured eight PFCs, including the four 
PFCs most frequently detected in NHANES, 
in 300 serum samples collected in 2009 from 
Texas children (157 girls and 143 boys) rang-
ing from birth to < 13 years of age (Table 1). 
Frequencies of detection of the analytes ranged 
from < 1% to 98% and were > 92% for 
PFHxS, PFOS, PFOA, and PFNA (Table 2). 
PFOSA and Et-PFOSA-AcOH were detected 
in < 2% of samples; Me-PFOSA-AcOH was 
detected in 36%, and PFDA was detected 
in 14% of the samples. For girls and boys 
combined, median serum concentrations 
were 1.20 ng/mL for PFHxS and PFNA, 
2.85 ng/mL for PFOA, and 4.10 ng/mL 
for PFOS (Table 2). Infants < 1 year of age 
(n = 25) had PFHxS concentrations ranging 
from non detectable to 4.0 ng/mL (median, 
0.5 ng/mL), PFNA concentrations from non-
detectable to 2.2 ng/mL (median, 0.6 ng/mL), 
Table 1. Age and sex distribution (n) of 300 children 
from Dallas, Texas.
Age (years) Boys Girls All
0 to < 1 15 10 25
1 to < 2 13 12 25
2 to < 3 16 9 25
3 to < 4 18 7 25
4 to < 5 10 15 25
5 to < 6 13 12 25
6 to < 7 12 13 25
7 to < 8 9 16 25
8 to < 9 7 18 25
9 to < 10 11 14 25
10 to < 11 11 13 24
11 to < 12 6 8 14
12 to < 13 2 10 12
Total 143 157 300










(n = 157)PFC All Boys Girls All Boys Girls
PFOA 97 99 98 0.1 2.70 2.90 2.85 13.50 9.60
PFOS 94 97 96 0.2 4.20 4.10 4.10 93.30 38.30
PFNA 95 99 97 0.1 1.20 1.30 1.20 55.80 4.20
PFHxS 93 92 93 0.1 1.20 1.10 1.20 31.20 9.60
Et-PFOSA-AcOH 0 < 1 < 1 0.2 < 0.2 < 0.2 < 0.2 < 0.2 0.70
Me-PFOSA-AcOH 36 36 36 0.2 < 0.2 < 0.2 < 0.2 28.90 13.40
PFDA 13 15 14 0.2 < 0.2 < 0.2 < 0.2 1.00 2.10
PFOSA 1 1 1 0.1 < 0.1 < 0.1 < 0.1 0.60 0.30
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PFOA from nondetectable to 8.8 ng/mL 
(median, 1.9 ng/mL), and PFOS from non-
detectable to 6 ng/mL (median, 2.4 ng/mL).
Median concentrations were very similar 
for girls and boys (Table 2). Further, we did 
not observe statistically significant differences 
in serum concentrations by sex for any of the 
PFCs examined (all Wilcoxon rank-sum tests 
p > 0.05).
For each of the four PFCs with detection 
frequencies > 92% (PFHxS, PFOS, PFOA, 
and PFNA), the Kruskal–Wallis test of overall 
differences among age groups (0 to < 3, 3 to 
< 6, 6 to < 9, 9 to < 13) was significant for 
boys alone, girls alone, and boys and girls 
combined (Table 3). For all children com-
bined and girls only, median values for all 
four PFCs were significantly lower for chil-
dren 0 to < 3 years of age compared with the 
older age groups. For boys, median concentra-
tions were not significantly different between 
3 to < 6 years and 0 to < 3 years age groups, 
but there were some significant differences 
for older age groups. Median values increased 
monotonically by age group for PFOS and 
PFHxS (in girls, boys, and girls and boys 
combined) but were generally consistent by 
age > 0 to < 3 years for PFOA and PFNA.
Serum concentrations of PFOS, PFNA, 
PFHxS, and PFOA were significantly cor-
related with age (Spearman rank correla-
tions 0.168–0.425, all p < 0.04) (Table 4). 
Correlations between PFOS, PFOA, PFNA, 
and PFHxS concentrations were positive and 
significant among girls, boys, and girls and 
boys combined (Spearman rank correlations 
0.525–0.812, all p < 0.0001).
Discussion
Our results suggest that serum concentra-
tions of PFOA, PFOS, PFNA, and PFHxS 
in our study population increased from birth 
until < 13 years of age. Those in the young-
est group, 0 to < 3 years, have significantly 
lower PFC serum concentrations than those 
in groups 6 to < 9 or 9 to < 13, except for 
PFOA and PFNA in boys. It is possible that 
concentrations may increase with age partly 
because of cumulative exposures to PFCs via 
food and dust intake (Fromme et al. 2009). 
It is also possible that younger children in 
our study population experienced lower 
exposure to some PFCs than older chil-
dren, because PFOS production stopped in 
2002 in the United States (3M Company 
2000), and PFOA release during manufactur-
ing has declined since the early 2000s (U.S. 
Environmental Protection Agency 2006). 
The discontinuation of production of some 
of these chemicals, coupled with their rela-
tively long half-life, could explain why older 
children had higher levels of these chemi-
cals. However, the relevance of the changes in 
manufacturing practices is difficult to deter-
mine, given the persistent nature of PFCs 
and the lack of information on baseline levels 
(e.g., PFC concentrations in the early 2000s 
for the older children) and on exposure path-
ways for our study population. Except for 
age and sex of the children, information on 
individual factors that might influence PFC 
levels, such as breast-feeding history, was not 
available, thus making it difficult to assess 
potential determinants of exposure (Fromme 
et al. 2010).





Post hoc pairwise testing (Dunn method) p-values
0 to < 3 3 to < 6 6 to < 9 9 to < 13 0 to < 3 vs. 3 to < 6 vs.
PFC/Sex n Med Max n Med Max n Med Max n Med Max 3 to < 6 6 to < 9 9 to < 13 6 to < 9 9 to < 13
PFOS ng/mL
Boys 44 2.3 10.5 41 2.8 23.3 28 6 76 30 7.05 93.3 < 0.0001 < 0.001 < 0.001 0.020 0.011
Girls 31 1.8 10.6 34 4.25 14.4 47 4.3 21.7 45 5.6 38.3 < 0.0001 < 0.001 < 0.001 < 0.001
Combined 75 2 10.6 75 3.7 23.3 75 5 76 75 6.3 93.3 < 0.0001 < 0.01 < 0.001 < 0.001 < 0.01
PFOA ng/mL
Boys 44 2.2 8.8 41 2.6 11.1 28 3.75 10.7 30 3.45 13.5 0.021 0.036
 Girls 31 1.8 9.6 34 3.3 6.2 47 2.9 7.6 45 3 6.1 0.0001 < 0.001 < 0.01 < 0.01
 Combined 75 2 9.6 75 3.1 11.1 75 3 10.7 75 3 13.5 < 0.0001 < 0.001 < 0.001 < 0.001
PFNA ng/mL
Boys 44 0.9 55.8 41 1.1 9.2 28 1.4 14.4 30 1.3 6 0.0091 0.013   
Girls 31 0.6 2.2 34 1.45 4.2 47 1.4 3.9 45 1.4 3.3 < 0.0001 < 0.001 < 0.001 < 0.001   
Combined 75 0.6 55.8 75 1.3 9.2 75 1.4 14.4 75 1.3 6 < 0.0001 < 0.001 < 0.001 < 0.001   
PFHxS ng/mL
Boys 44 0.6 4 41 1 14.6 28 1.5 31.2 30 1.7 9 0.0004 < 0.01 < 0.01   
 Girls 31 0.5 2 34 1.2 3.3 47 1.3 9.6 45 1.6 5.4 < 0.0001 < 0.001 < 0.001 < 0.001   
 Combined 75 0.5 4 75 1.1 14.6 75 1.3 31.2 75 1.6 9 < 0.0001 < 0.001 < 0.001 < 0.001   
Abbreviations: Med, median; Max, maximum.
Table 4. Spearman rank order correlations (rho) for age and serum concentrations of PFOS, PFOA, PFNA, and PFHxS.
Age at collection PFOS PFOA PFNA PFHxS
Group/PFC Spearman rho p-Value Spearman rho p-Value Spearman rho p-Value Spearman rho p-Value Spearman rho p-Value
Boys (n = 143)
PFOS 0.425 < 0.0001 0.805 < 0.0001 0.737 < 0.0001 0.812 < 0.0001
PFOA 0.264 0.0014 0.805 < 0.0001 0.770 < 0.0001 0.811 < 0.0001
PFNA 0.273 0.0010 0.737 < 0.0001 0.770 < 0.0001 0.648 < 0.0001
PFHxS 0.376 < 0.0001 0.812 < 0.0001 0.811 < 0.0001 0.648 < 0.0001
Girls (n = 157)
PFOS 0.402 < 0.0001 0.726 < 0.0001 0.632 < 0.0001 0.764 < 0.0001
PFOA 0.168 0.0356 0.726 < 0.0001 0.763 0.0000 0.635 < 0.0001
PFNA 0.215 0.0069 0.632 < 0.0001 0.763 < 0.0001 0.525 < 0.0001
PFHxS 0.423 < 0.0001 0.764 < 0.0001 0.635 < 0.0001 0.525 < 0.0001
Combined (boys and girls n = 300
PFOS 0.421 < 0.0001 0.768 < 0.0001 0.684 < 0.0001 0.784 < 0.0001
PFOA 0.220 0.0001 0.768 < 0.0001 0.766 < 0.0001 0.730 < 0.0001
PFNA 0.251 < 0.0001 0.684 < 0.0001 0.766 < 0.0001 0.583 < 0.0001
PFHxS 0.397 < 0.0001 0.784 < 0.0001 0.730 < 0.0001 0.583 < 0.0001
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Others have reported an association 
between age and PFC serum concentrations. 
Zhang et al. (2010b) observed significant posi-
tive associations between age and whole blood 
concentrations of several PFCs, including 
PFHxS, PFOS, PFNA, and PFDA, but not 
PFOA, in 184 Chinese children 0–10 years 
of age. The authors speculated that these asso-
ciations might have been related to dietary 
exposures, as PFCs have been detected in food 
worldwide (Zhang et al. 2010b). A positive 
association between age and PFC serum con-
centrations was also reported among adults 
in Norway and Australia (Haug et al. 2009; 
Kärrman et al. 2006) but was not evident in a 
study of convenience samples of blood, plasma, 
and serum from volunteer donors in the 
United States, Colombia, Belgium, Malaysia, 
Korea, and other countries (20–75 samples per 
source population) (Kannan et al. 2004).
There are conflicting data regarding sex 
differences in PFC concentrations in children. 
Zhang et al. (2010b) noted that median con-
centrations of four PFCs, including PFNA, 
PFOA, and PFOS, were slightly higher in 
whole blood samples from Chinese females 
(n = 82) compared with males (n = 163) 0–90 
years of age. Results from a study using sera 
collected in southeast Queensland, Australia, 
in 2006–2007 from 2,420 donors 0 to > 60 
years of age and pooled according to age 
showed no apparent sex differences in children 
(< 12 years of age) (Toms et al. 2009). In the 
present study, we also did not find a difference 
in children’s PFC serum concentrations based 
on sex.
The higher detection frequency for 
Me-PFOSA-AcOH versus Et-PFOSA-AcOH 
in our study population may be related to the 
use of these chemicals and subsequent expo-
sure routes for children: Me-PFOSA-AcOH 
is an oxidation product of 2-(N-methyl-
perfluoro octane sulfonamide) ethanol, used 
in carpets and textiles, whereas Et-PFOSA-
AcOH is used in paper products (Kato et al. 
2009a; Olsen et al. 2003).
In this study, we report serum PFC con-
centrations, which are measures of internal 
exposure, without attempting to address 
external exposures in a population of chil-
dren in Dallas, Texas. These values were lower 
than concentrations measured previously by 
others at different times, locations, and ages 
both in the United States and other coun-
tries. Differences in PFC concentrations in 
our study population compared with  others 
may also be related to age, country, use of 
whole blood versus serum, pooled versus indi-
vidual sampling, or the timing of specimen 
collection, which occurred later than in other 
studies and several years after production 
of some PFCs ceased in the United States 
(Calafat et al. 2006, 2007a, 2007b; CDC 
2010; Guruge et al. 2005; Hemat et al. 2010; 
Hölzer et al. 2008; Kato et al. 2009b; Olsen 
et al. 2004; Spliethoff et al. 2008; Toms et al. 
2009; Zhang et al. 2010b).
Higher serum concentrations of PFOS, 
PFHxS, and PFOA were reported by Frisbee 
et al. (2009, 2010) for children living in areas 
of the United States with known environ-
mental PFOA contamination. However, 
PFNA concentrations were similar in the C8 
study population (median, 1.6 ng/ mL) and 
our study population (median, 1.2 ng/ mL) 
(Frisbee et al. 2009, 2010). Median concen-
trations from birth to < 13 years were lower 
in our study population than median con-
centrations reported for NHANES 2007–
2008 ages 12–19 years (357 samples) for 
PFOS (11.3 ng/mL), PFOA (4.0 ng/mL), 
and PFHxS (2.3 ng/mL) and slightly higher 
for PFNA (1.4 ng/mL) (Kato et al. 2011). 
Our findings for Texas children from birth 
through 1 year in 2009 are consistent with 
ranges of median values reported for 110 
pooled blood spot samples taken at birth 
for congenital disease testing in 2,640 New 
York infants born between 1997 and 2007 
(Spliethoff et al. 2008). Concentrations in 
children from birth through age 1 year are 
also consistent with median concentrations in 
dried blood spots (generally from 2-day-old 
children) from 98 infants born in Texas in 
May 2007 (Kato et al. 2009b).
Dried blood spots may provide a potential 
matrix for assessing exposure to certain PFCs. 
We believe that blood spots, because of ease 
of collection compared with venipuncture, 
may play a role in the future for estimation of 
internal exposure to PFCs. To the best of our 
knowledge, partitioning ratios between blood 
spot and serum PFC levels have not yet been 
determined even as partial validation for the 
use of blood spots from whole blood instead 
of serum PFC measurements, the current gold 
standard for biomonitoring. We include pre-
vious dried blood spot results only as illustra-
tive of other PFC exposure studies in children 
using different approaches rather than the 
validated (serum) methods we employed. Our 
study of Dallas children is representative only 
of children < 12 years of age who had blood 
samples drawn at Children’s Medical Center. 
Further research should be performed in a 
large representative sample to determine the 
serum concentrations of young children in 
the United States.
Conclusions
In a convenience sample of 300 individual 
serum samples from a Dallas, Texas, medi-
cal facility, we detected four PFCs in at least 
92% of the tested serum samples. Serum con-
centrations were lowest in children age 0 to 
< 3 years, and concentrations of some PFCs 
increased from birth through < 13 years of 
age. Major changes in PFC manufacturing, 
including discontinued production of PFOS 
and of PFOA at some U.S. facilities, occurred 
years before sample collection for this study. 
Our results show that several PFCs were detect-
able in children in Dallas, Texas, in 2009, 
including those born after changes in PFC 
manufacturing occurred. Data from a larger, 
more representative sample are needed to deter-
mine current PFC concentrations in the gen-
eral population of U.S. children and evaluate 
relevant pathways of exposure. Additionally, 
further epidemiological studies will be nec-
essary to determine whether PFC exposures 
in children at the concentrations detected are 
associated with adverse health outcomes.
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